About Us

Medera Company Overview

As a clinical-stage biopharmaceutical company, Medera is developing novel gene- and cell-based therapeutic candidates using our proprietary intracoronary delivery methodology, and leveraging its cutting-edge bioengineered human mini-Heart preclinical screening platform with customized automated screening and data analysis technologies developed by our founding scientists, portfolio companies and partners.

Led by world-renowned pioneers with decades of experience in human cardiac tissue engineering, gene & cell therapy, vector design, drug development, bio-manufacturing, clinical cardiology and heart failure management, as well as commercialization, we have developed a robust pipeline of clinical stage gene therapy candidates for heart diseases, encompassing both common diseases (e.g., heart failure with reduced ejection fraction, HFrEF, and heart failure with preserved ejection fraction, HFpEF) and rare diseases (e.g., Duchenne muscular dystrophy-associated cardiomyopathy, DMD-CM). This strategy allows us to tackle societal and healthcare burdens most amenable to our scientifically validated and technologically driven approaches. Our preclinical pipeline also covers pulmonary (e.g., pulmonary hypertension, pulmonary fibrosis) and vascular (e.g., arteriovenous fistula failure) diseases. We aim to develop next-generation therapeutics, such as gene therapies, for both hereditary and acquired diseases, that promise to be affordable and deliverable within diverse health care systems.